' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.
Harrer, A; Pilz, G; Oppermann, K; Sageder, M; Afazel, S; Haschke-Becher, E; Rispens, T; de Vries, A; McCoy, M; Stevanovic, V; Hitzl, W; Trinka, E; Kraus, J; Sellner, J; Wipfler, P;
Clin Immunol. 2017; 176: 87-93.
Originalarbeiten (Zeitschrift)


Harrer Andrea
Haschke-Becher Elisabeth
Hitzl Wolfgang
Kraus Jörg
McCoy Mark R.
Oppermann Katrin
Pilz Georg
Sellner Johann
Trinka Eugen
Wipfler Peter


Natalizumab (NZB) discontinuation during a treatment change is associated with recurrence of disease activity in a significant proportion of multiple sclerosis (MS) patients. The immunological basis why disease reactivation occurs in selected patients is unresolved. In search of a prognostic biomarker for a safe and effective transition from NZB to fingolimod, we monitored five parameters related to pharmacokinetic and pharmacodynamic effects of the two drugs in 12 MS patients until six months on fingolimod. Clearance of free and cell-bound NZB, re-expression of alpha-4, and fingolimod-mediated changes on CD8+ and CD4+ T cell subsets showed pronounced interindividual variability. Higher frequencies of memory CD8+ T cells after six months on fingolimod were the sole association with disease reactivation. None of the investigated parameters thus had potential as prognostic biomarker for the outcome of the switch. Our findings rather support the thesis of broad interindividual differences in the immunopathogenesis of MS. Copyright © 2017 Elsevier Inc. All rights reserved.

Find related publications in this database (Keywords)

Multiple sclerosis
Treatment change
Flow cytometry